O	0	9	Promoting
O	10	16	weight
O	17	21	loss
O	22	29	through
B-intervention	30	34	diet
I-intervention	35	38	and
I-intervention	39	47	exercise
O	48	50	in
O	51	61	overweight
O	62	64	or
O	65	70	obese
O	71	77	breast
O	78	84	cancer
O	85	94	survivors
O	95	96	(
O	96	103	InForma
O	103	104	)
O	104	105	:
O	106	111	study
O	112	120	protocol
O	121	124	for
O	125	126	a
O	127	137	randomized
O	138	148	controlled
O	149	154	trial
O	154	155	.

O	156	160	Most
O	161	166	women
O	167	171	with
O	172	178	breast
O	179	185	cancer
O	186	196	experience
O	197	198	a
O	199	210	progressive
O	211	217	weight
O	218	222	gain
O	223	229	during
O	230	233	and
O	234	239	after
O	240	249	treatment
O	249	250	.

O	251	258	Obesity
O	259	261	is
O	262	272	associated
O	273	277	with
O	278	280	an
O	281	290	increased
O	291	295	risk
O	296	298	of
O	299	309	recurrence
O	309	310	,
O	311	324	contralateral
O	325	331	breast
O	332	338	cancer
O	338	339	,
O	340	343	and
O	344	349	death
O	349	350	.

O	351	359	Physical
O	360	368	activity
O	369	374	after
O	375	381	cancer
O	382	391	diagnosis
O	392	395	has
O	396	400	been
O	401	409	reported
O	410	412	to
O	413	417	have
O	418	426	positive
O	427	434	effects
O	435	437	on
O	438	442	body
O	443	454	composition
O	455	458	and
O	459	466	quality
O	467	469	of
O	470	474	life
O	474	475	.

O	476	478	We
O	479	486	present
O	487	490	the
O	491	499	protocol
O	500	502	of
O	503	506	the
O	507	514	InForma
O	515	520	study
O	520	521	,
O	522	523	a
O	524	529	trial
O	530	537	testing
O	538	541	the
O	542	550	efficacy
O	551	553	of
O	554	556	an
O	557	569	intervention
O	570	572	on
O	573	579	weight
O	580	584	loss
O	585	586	(
O	586	587	â‰¥
O	587	588	5
O	589	590	%
O	591	593	of
O	594	597	the
O	598	606	baseline
O	607	611	body
O	612	618	weight
O	618	619	)
O	620	622	in
O	623	624	a
O	625	630	group
O	631	633	of
O	634	644	overweight
O	645	647	or
O	648	653	obese
O	654	660	breast
O	661	667	cancer
O	668	677	survivors
O	677	678	.

O	679	683	This
O	684	686	is
O	687	688	a
O	689	693	four
O	693	694	-
O	694	697	arm
O	698	708	randomized
O	709	719	controlled
O	720	725	trial
O	725	726	.

O	727	735	Patients
O	736	740	will
O	741	748	receive
O	749	750	a
O	751	752	6
O	752	753	-
O	753	758	month
O	759	771	intervention
O	772	775	and
O	776	778	be
O	779	787	followed
O	788	791	for
O	792	793	a
O	794	801	further
O	802	804	18
O	805	811	months
O	811	812	.

O	813	825	Intervention
O	826	828	is
O	829	837	designed
O	838	840	to
O	841	848	improve
O	849	858	adherence
O	859	861	to
O	862	863	a
O	864	871	healthy
O	872	876	diet
O	877	880	and
O	880	881	/
O	881	883	or
O	884	886	to
O	887	895	increase
O	896	904	physical
O	905	913	activity
O	913	914	,
O	915	921	taking
O	922	931	advantage
O	932	934	of
O	935	936	a
O	937	942	wrist
O	942	943	-
O	943	948	based
O	949	957	activity
O	958	965	monitor
O	965	966	.

O	967	979	Participants
O	980	984	will
O	985	987	be
O	988	997	recruited
O	998	1003	among
B-eligibility	1004	1014	overweight
I-eligibility	1015	1017	or
I-eligibility	1018	1023	obese
I-eligibility	1024	1030	breast
I-eligibility	1031	1037	cancer
I-eligibility	1038	1046	patients
I-eligibility	1047	1054	treated
I-eligibility	1055	1057	at
I-eligibility	1058	1061	the
I-eligibility	1062	1070	European
I-eligibility	1071	1080	Institute
I-eligibility	1081	1083	of
I-eligibility	1084	1092	Oncology
I-eligibility	1092	1093	,
I-eligibility	1094	1099	after
I-eligibility	1100	1110	completion
I-eligibility	1111	1113	of
I-eligibility	1114	1122	eventual
I-eligibility	1123	1131	adjuvant
I-eligibility	1132	1144	chemotherapy
I-eligibility	1145	1148	and
I-eligibility	1148	1149	/
I-eligibility	1149	1151	or
I-eligibility	1152	1164	radiotherapy
O	1164	1165	.

O	1166	1168	It
O	1169	1171	is
O	1172	1181	envisaged
O	1182	1186	that
B-total-participants	1187	1190	260
O	1191	1199	patients
O	1200	1204	will
O	1205	1207	be
O	1208	1218	randomized
O	1219	1223	into
O	1224	1228	four
O	1229	1233	arms
O	1233	1234	:
O	1235	1242	Dietary
O	1243	1255	Intervention
O	1255	1256	;
O	1257	1265	Physical
O	1266	1274	Activity
O	1275	1287	Intervention
O	1287	1288	;
O	1289	1297	Physical
O	1298	1306	Activity
O	1307	1310	and
O	1311	1318	Dietary
O	1319	1331	Intervention
O	1331	1332	;
O	1333	1336	and
O	1337	1341	Less
O	1342	1351	Intensive
O	1352	1364	Intervention
O	1364	1365	.

O	1366	1371	Women
O	1372	1376	will
O	1377	1379	be
O	1380	1387	offered
O	1388	1402	individualized
O	1403	1413	counseling
O	1414	1424	consisting
O	1425	1427	of
O	1428	1432	face
O	1432	1433	-
O	1433	1435	to
O	1436	1440	face
O	1441	1451	discussion
O	1452	1455	and
O	1456	1461	phone
O	1462	1467	calls
O	1468	1470	in
O	1471	1479	addition
O	1480	1482	to
O	1483	1488	group
O	1489	1497	meetings
O	1497	1498	.

O	1499	1500	A
O	1501	1513	motivational
O	1514	1526	interviewing
O	1527	1535	approach
O	1536	1540	will
O	1541	1543	be
O	1544	1548	used
O	1549	1551	to
O	1552	1561	encourage
O	1562	1568	health
O	1569	1577	behavior
O	1578	1584	change
O	1584	1585	.

O	1586	1589	All
O	1590	1602	participants
O	1603	1607	will
O	1608	1610	be
O	1611	1616	given
O	1617	1618	a
O	1619	1628	pedometer
O	1629	1635	device
O	1636	1638	to
O	1639	1646	monitor
O	1647	1652	their
O	1653	1661	physical
O	1662	1670	activity
O	1670	1671	.

O	1672	1684	Participants
O	1684	1685	'
O	1686	1693	dietary
O	1694	1700	intake
O	1701	1705	will
O	1706	1708	be
O	1709	1719	repeatedly
O	1720	1728	assessed
O	1729	1734	using
O	1735	1736	a
O	1737	1746	validated
O	1747	1751	food
O	1752	1761	frequency
O	1762	1775	questionnaire
O	1775	1776	.

O	1777	1789	Participants
O	1789	1790	'
O	1791	1798	quality
O	1799	1801	of
O	1802	1806	life
O	1807	1810	and
O	1811	1818	anxiety
O	1819	1823	will
O	1824	1826	be
O	1827	1835	assessed
O	1836	1840	with
O	1841	1844	the
O	1845	1855	Functional
O	1856	1866	Assessment
O	1867	1869	of
O	1870	1876	Cancer
O	1877	1884	Therapy
O	1884	1885	-
O	1885	1891	Breast
O	1892	1895	and
O	1896	1899	the
O	1900	1905	State
O	1905	1906	-
O	1906	1911	Trait
O	1912	1919	Anxiety
O	1920	1929	Inventory
O	1930	1944	questionnaires
O	1944	1945	.

O	1946	1951	Blood
O	1952	1959	samples
O	1960	1964	will
O	1965	1967	be
O	1968	1977	collected
O	1978	1980	at
O	1981	1989	baseline
O	1990	1993	and
O	1994	2000	follow
O	2000	2001	-
O	2001	2003	up
O	2004	2010	visits
O	2011	2013	to
O	2014	2020	assess
O	2021	2026	lipid
O	2027	2030	and
O	2031	2038	hormone
O	2039	2047	profiles
O	2047	2048	.

O	2049	2053	Body
O	2054	2065	composition
O	2066	2070	will
O	2071	2073	be
O	2074	2084	repeatedly
O	2085	2093	assessed
O	2094	2099	using
O	2100	2113	bioelectrical
O	2114	2123	impedance
O	2124	2130	vector
O	2131	2139	analysis
O	2140	2143	for
O	2144	2155	identifying
O	2156	2163	changes
O	2164	2166	of
O	2167	2170	fat
O	2171	2174	and
O	2175	2178	fat
O	2178	2179	-
O	2179	2183	free
O	2184	2188	mass
O	2188	2189	.

O	2190	2195	Women
O	2196	2205	allocated
O	2206	2208	to
O	2209	2212	the
O	2213	2217	less
O	2218	2227	intensive
O	2228	2240	intervention
O	2241	2244	arm
O	2245	2249	will
O	2250	2252	be
O	2253	2263	considered
O	2264	2266	as
O	2267	2270	the
B-control	2271	2278	control
I-control	2279	2284	group
O	2284	2285	.

O	2286	2291	While
O	2292	2297	there
O	2298	2300	is
O	2301	2302	a
O	2303	2309	rising
O	2310	2317	concern
O	2318	2323	about
O	2324	2327	the
O	2328	2332	role
O	2333	2335	of
O	2336	2343	obesity
O	2344	2346	in
O	2347	2353	cancer
O	2354	2364	recurrence
O	2365	2368	and
O	2369	2377	survival
O	2377	2378	,
O	2379	2383	this
O	2384	2389	trial
O	2390	2394	with
O	2395	2398	its
O	2399	2404	multi
O	2404	2405	-
O	2405	2408	arm
O	2409	2415	design
O	2415	2416	,
O	2417	2429	motivational
O	2430	2438	approach
O	2439	2442	and
O	2443	2446	use
O	2447	2449	of
O	2450	2451	a
O	2452	2461	pedometer
O	2462	2468	device
O	2469	2473	will
O	2474	2481	provide
O	2482	2491	important
O	2492	2500	insights
O	2501	2510	regarding
O	2511	2514	the
O	2515	2519	most
O	2520	2529	effective
O	2530	2538	approach
O	2539	2541	in
O	2542	2551	promoting
O	2552	2558	weight
O	2559	2566	control
O	2567	2569	in
O	2570	2576	breast
O	2577	2583	cancer
O	2584	2593	survivors
O	2593	2594	.

O	2595	2609	ISRCTN53325751
O	2610	2611	(
O	2611	2623	registration
O	2624	2628	date
O	2628	2629	:
O	2630	2632	16
O	2633	2640	October
O	2641	2645	2015
O	2645	2646	)
O	2646	2647	;
O	2648	2662	ClinicalTrials
O	2662	2663	.
O	2663	2666	gov
O	2667	2678	NCT02622711
O	2679	2680	(
O	2680	2692	registration
O	2693	2697	date
O	2697	2698	:
O	2699	2700	2
O	2701	2709	December
O	2710	2714	2015
O	2714	2715	)
O	2715	2716	.
